<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069966</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316466</org_study_id>
    <secondary_id>THERADEX-AZA-II-02</secondary_id>
    <secondary_id>CWRU-NOVU-1403</secondary_id>
    <secondary_id>SUNY-HSC-4849</secondary_id>
    <secondary_id>NOVUSPHARMA-AZA-II-02</secondary_id>
    <nct_id>NCT00069966</nct_id>
  </id_info>
  <brief_title>Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse</brief_title>
  <official_title>A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone,&#xD;
      and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing&#xD;
      or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients who have relapsed aggressive non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of pixantrone, cytarabine, methylprednisolone, and&#xD;
           cisplatin in patients with aggressive non-Hodgkin's lymphoma in first relapse.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the validity and safety of this regimen as a mobilization regimen before&#xD;
           high-dose chemotherapy with stem cell support in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
        -  Salvage therapy: Patients receive pixantrone IV over 1 hour on day 1; cisplatin IV over&#xD;
           30 minutes on days 1-4; methylprednisolone IV over 15-30 minutes on days 1-5; and&#xD;
           cytarabine IV over 2 hours on day 5. Treatment repeats every 21 days for 2 courses in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After 2 courses of salvage therapy, patients are re-evaluated and treated as follows:&#xD;
&#xD;
        -  Complete response (CR) or partial response (PR): Patients with a CR or PR who are&#xD;
           suitable candidates for autologous stem cell transplantation (ASCT) proceed to&#xD;
           mobilization therapy, high-dose chemotherapy, and ASCT. Patients with a CR or PR who are&#xD;
           unsuitable candidates for ASCT continue to receive salvage therapy for up to 6 courses&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Stable disease: Patients with stable disease continue to receive salvage therapy for up&#xD;
           to 6 courses. Patients who have a CR or PR after 3-4 courses of salvage therapy and who&#xD;
           are suitable candidates for ASCT proceed to mobilization therapy, high-dose&#xD;
           chemotherapy, and ASCT off study at the investigator's discretion.&#xD;
&#xD;
             -  Mobilization therapy (optional regimen; regimen used for mobilization is at the&#xD;
                investigator's discretion): Patients receive rituximab* IV on days 1 and 7;&#xD;
                pixantrone IV over 1 hour on day 2; cisplatin IV over 30 minutes on days 2-5;&#xD;
                cytarabine IV over 2 hours on day 6; and methylprednisolone IV over 15-30 minutes&#xD;
                on days 2-6. Patients also receive filgrastim (G-CSF) subcutaneously once daily&#xD;
                beginning on day 7 and continuing until blood counts recover. Patients receive 1 or&#xD;
                more courses of mobilization therapy during which stem cells are harvested.&#xD;
                Patients then proceed to high-dose chemotherapy and subsequent re-infusion of&#xD;
                harvested stem cells.&#xD;
&#xD;
      NOTE: *If this mobilization regimen is used, patients with T-cell lymphoma do not receive&#xD;
      rituximab&#xD;
&#xD;
        -  High-dose chemotherapy and ASCT: Patients receive high-dose chemotherapy and ASCT per&#xD;
           institutional standard practice.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pixantrone dimaleate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Any stage, with or without B symptoms&#xD;
&#xD;
               -  The following subtypes are eligible:&#xD;
&#xD;
                    -  Diffuse large cell (B and T cell types)&#xD;
&#xD;
                    -  Anaplastic large cell&#xD;
&#xD;
                    -  Diffuse mixed cell&#xD;
&#xD;
                    -  Immunoblastic large cell&#xD;
&#xD;
                    -  Follicular large cell&#xD;
&#xD;
                    -  Transformed follicular NHL&#xD;
&#xD;
                    -  Diffuse aggressive not otherwise classified&#xD;
&#xD;
                    -  Burkitt-like lymphoma&#xD;
&#xD;
          -  Bone marrow positive or negative&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  Patients with bone marrow as the only site of disease are eligible without a&#xD;
                  measurable lesion&#xD;
&#xD;
          -  No more than 1 episode of progressive disease, occurring after a response (complete&#xD;
             response [CR], complete response unconfirmed [CR_u], or partial response [PR]) to&#xD;
             prior chemotherapy* NOTE: *Patients with less than a CR, CRu, or PR and no&#xD;
             progression, but who are good candidates for high-dose chemotherapy with stem cell&#xD;
             support may be eligible (will be decided on an individual basis)&#xD;
&#xD;
          -  No chemotherapy-refractory disease, defined as follows:&#xD;
&#xD;
               -  Stable or progressive disease documented at restaging immediately after the&#xD;
                  completion of induction therapy&#xD;
&#xD;
          -  No lymphoblastic lymphoma, or mantle cell lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3* NOTE: *Lower values may be accepted if clearly&#xD;
             due to bone marrow involvement by lymphoma&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  AST or ALT no greater than 2.0 times ULN*&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.0 times ULN*&#xD;
&#xD;
          -  No history or clinical symptoms of hepatitis B or hepatitis C virus&#xD;
&#xD;
               -  Patients with seropositivity due to prior vaccination for hepatitis B are&#xD;
                  eligible NOTE: *Higher values may be accepted if clearly due to liver involvement&#xD;
                  by lymphoma&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 50% by MUGA&#xD;
&#xD;
          -  No clinically significant cardiovascular abnormalities&#xD;
&#xD;
          -  No New York Heart Association grade II-IV cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No severe cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No clinically significant neurological abnormalities&#xD;
&#xD;
          -  No condition that would preclude study safety or interfere with study results&#xD;
&#xD;
          -  No concurrent serious uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior rituximab immediately after the first chemotherapy regimen allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 6 months since prior anthracycline therapy (e.g., cyclophosphamide,&#xD;
             doxorubicin, vincristine, and prednisone [CHOP])&#xD;
&#xD;
          -  More than 2 years since prior fludarabine&#xD;
&#xD;
          -  More than 2 years since prior nitrosoureas&#xD;
&#xD;
          -  More than 1 year since prior platinum-based chemotherapy or cytarabine, unless a CR or&#xD;
             CR_u was achieved&#xD;
&#xD;
          -  No prior cumulative dose of cisplatin greater than 600 mg/m^2&#xD;
&#xD;
          -  No prior single or cumulative dose of doxorubicin greater than 450 mg/m^2&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the whole pelvis&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major thoracic and/or abdominal surgery&#xD;
&#xD;
          -  At least 1 week since prior minor surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
               -  Alopecia allowed&#xD;
&#xD;
               -  Grade 1 peripheral neuropathy allowed&#xD;
&#xD;
          -  More than 30 days since prior participation in another investigational drug study&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M. Vose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates - Craycroft Road Offices</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712-2254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933-1181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Denver Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Clinical &amp; Laboratory Physicians</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco, Hernando Oncology Associates, P.A.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markey Cancer Center at University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center - Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hematology-Oncology Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center - Canton Office</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates-West</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112-4414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Northern Virginia Hematology Oncology, P.C. - Fairfax</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Auxilio Mutuo</name>
      <address>
        <city>Hato Rey</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>July 4, 2009</last_update_submitted>
  <last_update_submitted_qc>July 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2009</last_update_posted>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pixantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

